Search results
Showing 31 to 45 of 65 results for early and locally advanced breast cancer
with 40 Gy in 15 fractions over 3 weeks in people with early or locally advanced invasive breast...
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
Past technology appraisal appeals and decisions
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.
women:- Is neoadjuvant endocrine therapy safe in premenopausal women with early breast cancer? Any explanatory...
benefit for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer? Any explanatory...
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.
NG101/1 Question Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for...
virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the...
virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the...
delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is...
delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is...
Recommendation ID NG101/3 Question Breast reconstruction:- What are the long-term outcomes for breast reconstruction in...
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .